GIVING LIFE TO SCIENCE®

We are dedicated to giving life to science and transforming innovation into value

Strong track record of clinical success, outperforming the biopharma industry average by 6x1
29
New therapeutics and therapeutic candidates generated from PureTech's R&D engine
3
Taken from inception at PureTech to U.S. Food and Drug Administration approval
Unlocking the Potential of Validated Efficacy

We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine

Seasoned Senior Leadership

Our team has overseen R&D of therapeutics supporting more than 15 regulatory approvals and led several multi-billion dollar strategic transactions

Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

News & Press

Press releases
2026-07-02
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Press releases
2026-07-02
PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)